Dr Jennifer Martin Talks About the Effectiveness of Cognitive Behavioral Treatment for Insomnia

In this video, Jennifer Martin, PhD, Assistant Professor, UCLA, David School of Medicine, discusses how the effectiveness of cognitive behavioral treatment for insomnia among patients with dementia compare with current pharmacologic strategies.

Related Videos

Related Content

Advertisement

Published: July 1st 2025 | Updated: June 30th 2025

PROs Affirm Zongertinib’s Combination of Strong Response Rates With Low Toxicity

Joshua K. Sabari, MD Interview by Mary Caffrey

Joshua K. Sabari, MD, of NYU Langone Health discusses promising results for zongertinib in HER2-mutant NSCLC; the tyrosine kinase inhibitor offers high response rates and improved quality of life with minimal toxicity.

August 29th 2023

The Importance of Examining and Preventing Atrial Fibrillation

Maggie L. Shaw

At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.

June 26th 2025

Deep Learning Biomarkers Help Uncover ENV-101 Treatment Effects in IPF

Hayden E. Klein

At 12 weeks, patients treated with ENV-101 showed statistically significant increases in lung volume compared with those receiving placebo.

June 28th 2022

Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions

Matthew Gavidia

On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.

June 25th 2025

First-Line Rucaparib Maintenance Reduces Progression Risk Across Prognostic Subgroups in HRD– High-Grade Ovarian Cancer

Chris Ryan

Rucaparib maintenance improved progression-free survival (PFS) in homologous recombination deficiency (HRD)-negative advanced ovarian cancer, irrespective of baseline prognostic factors.

June 24th 2025

Targeting the Root of gMG With Inebilizumab: A Q&A With Richard Nowak, MD, MS

Maggie L. Shaw Richard J. Nowak, MD, MS

In this interview, Richard J. Nowak, MD, MS, principal investigator of the MINT trial of inebilizumab for generalized myasthenia gravis (gMG), discusses the trial’s key findings, including significant improvements in patient- and physician-assessed outcomes, as well as longer-term implications and future areas of investigation.

Related Content

Advertisement

Published: July 1st 2025 | Updated: June 30th 2025

PROs Affirm Zongertinib’s Combination of Strong Response Rates With Low Toxicity

Joshua K. Sabari, MD Interview by Mary Caffrey

Joshua K. Sabari, MD, of NYU Langone Health discusses promising results for zongertinib in HER2-mutant NSCLC; the tyrosine kinase inhibitor offers high response rates and improved quality of life with minimal toxicity.

August 29th 2023

The Importance of Examining and Preventing Atrial Fibrillation

Maggie L. Shaw

At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.

June 26th 2025

Deep Learning Biomarkers Help Uncover ENV-101 Treatment Effects in IPF

Hayden E. Klein

At 12 weeks, patients treated with ENV-101 showed statistically significant increases in lung volume compared with those receiving placebo.

June 28th 2022

Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions

Matthew Gavidia

On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.

June 25th 2025

First-Line Rucaparib Maintenance Reduces Progression Risk Across Prognostic Subgroups in HRD– High-Grade Ovarian Cancer

Chris Ryan

Rucaparib maintenance improved progression-free survival (PFS) in homologous recombination deficiency (HRD)-negative advanced ovarian cancer, irrespective of baseline prognostic factors.

June 24th 2025

Targeting the Root of gMG With Inebilizumab: A Q&A With Richard Nowak, MD, MS

Maggie L. Shaw Richard J. Nowak, MD, MS

In this interview, Richard J. Nowak, MD, MS, principal investigator of the MINT trial of inebilizumab for generalized myasthenia gravis (gMG), discusses the trial’s key findings, including significant improvements in patient- and physician-assessed outcomes, as well as longer-term implications and future areas of investigation.